Applied Genetic Technologies Corporation (AGTC)

[Stingray]

(Nasdaq: AGTC). Mutations in the GJB2 gene are the most common cause of congenital hearing loss and typically result in moderate to severe hearing impairment.

"We are excited to present these preclinical results for OTO-825 that build on our previous presentations demonstrating gene expression in support cells of the cochlear, which are the target cells for GJB2 gene therapy, using novel AAV vectors identified through our collaboration with AGTC,” said Alan C. Foster, Ph.D., chief scientific officer of Otonomy. “Based on these encouraging results that demonstrate hearing recovery and improved cochlear morphology following OTO-825 administration, the companies have initiated IND-enabling activities and look forward to providing additional details of the program in the next several months.”

https://finance.yahoo.com/news/otonomy-agtc-present-preclinical-proof-113000630.html